For the quarter ending 2026-03-31, KRYS has $1,396,967K in assets. $120,238K in debts. $501,313K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 501,313 | 496,304 | 392,604 | 353,829 |
| Short-term investments | 322,092 | 331,487 | 338,465 | 328,157 |
| Accounts receivable, net | 127,022 | 127,425 | 129,633 | 111,439 |
| Inventory | 42,646 | 40,475 | 37,632 | 31,041 |
| Prepaid taxes | 10,642 | 14,006 | 10,103 | - |
| Prepaid expenses and other current assets | 16,026 | 14,905 | 17,213 | 16,881 |
| Total current assets | 1,019,741 | 1,024,602 | 925,650 | 841,347 |
| Property and equipment, net | 153,582 | 150,776 | 148,871 | 150,388 |
| Long-term investments | 193,485 | 128,066 | 133,113 | 138,807 |
| Right-of-use assets | 7,035 | 7,239 | 7,447 | 7,655 |
| Deferred tax asset, net of valuation allowance | 22,824 | 22,824 | 24,680 | - |
| Other non-current assets | 300 | 287 | 333 | 197 |
| Total assets | 1,396,967 | 1,333,794 | 1,240,094 | 1,138,394 |
| Accounts payable | 4,089 | 3,238 | 2,097 | 7,124 |
| Current portion of lease liability | 1,800 | 1,771 | 1,698 | 1,617 |
| Accrued rebates | 70,717 | 58,181 | 55,769 | 51,638 |
| Accrued expenses and other current liabilities | 31,196 | 39,752 | 31,704 | 26,517 |
| Total current liabilities | 107,802 | 102,942 | 91,268 | 86,896 |
| Lease liability | 7,312 | 7,568 | 7,813 | 8,064 |
| Other long-term liabilities | 5,124 | 3,724 | 3,137 | 2,787 |
| Total liabilities | 120,238 | 114,234 | 102,218 | 97,747 |
| Additional paid-in capital | 1,198,257 | 1,194,261 | 1,164,013 | 1,146,092 |
| Accumulated other comprehensive (loss) gain | -1,623 | 1,136 | 1,100 | 1,157 |
| Retained earnings | 80,095 | 24,163 | -27,237 | -106,602 |
| Total stockholders equity | 1,276,729 | 1,219,560 | 1,137,876 | 1,040,647 |
| Total liabilities and stockholders equity | 1,396,967 | 1,333,794 | 1,240,094 | 1,138,394 |
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)